PYC Therapeutics Ltd
PYC
Company Profile
Business description
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company’s drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
Contact
6 Verdun Street
Harry Perkins Institute of Medical Research
Nedlands
PerthWA6009
AUST: +61 861510992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.30 | 60.00 | 0.68% |
| CAC 40 | 7,828.91 | 20.74 | 0.27% |
| DAX 40 | 24,231.68 | 71.04 | 0.29% |
| Dow JONES (US) | 44,459.65 | 88.14 | 0.20% |
| FTSE 100 | 9,002.12 | 4.06 | 0.05% |
| HKSE | 24,531.08 | 327.76 | 1.35% |
| NASDAQ | 20,640.33 | 54.80 | 0.27% |
| Nikkei 225 | 39,678.02 | 218.40 | 0.55% |
| NZX 50 Index | 12,689.63 | 10.94 | 0.09% |
| S&P 500 | 6,268.56 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,630.30 | 59.90 | 0.70% |
| SSE Composite Index | 3,505.00 | 14.65 | -0.42% |